Professor Ros Corney at the University of Greenwich has been funded by Breast Cancer Campaign to study the issues faced by young women with breast cancer who haven’t had children - an area in which there has previously been very few studies.
Pharmaceutical company, Roche, has announced the license of a new type of breast cancer drug, Kadcyla, which has been shown to prolong the life expectancy and quality of life of women with advanced HER2-positive breast cancer.
Kadcyla is an antibody-drug conjugate (ADC), the first of its kind in breast cancer, which can deliver chemotherapy straight to the cancer cells. This means smaller amounts are needed and less collateral damage of surrounding cells is caused.
A new campaign launched today, backed by Breast Cancer Campaign and several other members of the AMRC (Association of Medical Research Charities), aims to raise awareness of the value of patient data for research.
When reading the guardian.com blog Patients deserve the truth: health screening can do more harm than good (Friday 3 January 2014) we were disappointed by the misrepresentation of Breast Cancer Campaign and the comment we gave at the time of the launch of the new breast screening leaflet.
Macmillan Cancer Support has produced new calculations to show that deaths from breast, prostate and bowel cancer will decrease by 2020. With the figures for breast cancer showing 36% of breast cancer patients will ultimately die from the disease in 2020, down from 61% in 1992.
Breast Cancer Campaign is a charity registered by the Charity Commission for England and Wales (no. 299758) and a company limited by guarantee registered in England (no. 05074725) whose registered office is at Clifton Centre, 110 Clifton Street, London EC2A 4HT.